Chardan Capital analyst Geulah Livshits downgraded Tocagen Inc (TOCA) to Hold today and set a price target of $1. The company’s shares closed last Monday at $0.93, close to its 52-week low of $0.73.
Livshits said:
“We therefore reduce our price target to $1 and downgrade to Neutral.”
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 10.6% and a 55.6% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Logicbio Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Tocagen Inc is a Hold with an average price target of $1, a 33.1% upside from current levels. In a report released today, Robert W. Baird also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.80 and a one-year low of $0.73. Currently, Tocagen Inc has an average volume of 233.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy compan. It focuses on the development of product candidates designed to activate a patient’s immune system against their own cancer from within. It is in the business of discovery, development, and commercialization of products for the treatment of cancer.